Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991501 | 0.87 | HPGD (0.46) | LMNAHPGDPARP15PARP10 | |
| SCHEMBL8215629 | 0.86 | LMNA (0.63) | LMNAL3MBTL1TSHRHPGDMCL1 | |
| SCHEMBL21992545 | 0.83 | BRD4 (0.45) | FFAR1FFAR4PDK2 | |
| SCHEMBL3080731 | 0.82 | L3MBTL1 (0.56) | L3MBTL1FFAR1FFAR4TSHRMCL1 | |
| SCHEMBL21991801 | 0.82 | PDE3B (0.42) | L3MBTL1FFAR1FFAR4HPGDPARP15 | |
| SCHEMBL30888680 | 0.82 | LMNA (0.54) | LMNAL3MBTL1FFAR1FFAR4TSHR | |
| SCHEMBL21991944 | 0.80 | PPARA (0.49) | FFAR4TSHRPPARGPPARAPARP15 | |
| SCHEMBL30665865 | 0.80 | LMNA (0.55) | LMNAL3MBTL1TSHRHPGDMCL1 | |
| SCHEMBL2775814 | 0.80 | L3MBTL1 (0.58) | LMNAL3MBTL1FFAR1TSHRMCL1 | |
| SCHEMBL26654446 | 0.80 | LMNA (0.55) | LMNAL3MBTL1TSHRHPGDMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885FFAR1 147/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885FFAR1 147/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885FFAR1 147/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885FFAR1 147/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885FFAR1 147/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885FFAR1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.